Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, announced that Derek Hicks was appointed CEO. With more than 25 years of leadership in the pharmaceutical and biotech sectors, Derek brings a strong track record of transformative business development and experience in a wide range of disease areas, including oncology.
"Derek brings an exceptional blend of skills, experience and strategic acumen, in addition to a collaborative style, all of which are vital as Rezo continues to redefine treatments for cancer and other complex diseases," said Rezo Chairman George Scangos. "With Derek at the helm, we are strongly positioned to accelerate our cutting-edge drug-discovery capabilities and unlock new frontiers of drug discovery and development."
"Derek's appointment represents the beginning of a pivotal chapter in Rezo's evolution," said Rezo President and Co-Founder Nevan Krogan. "The strides we've made in advancing our platform and pipeline speak to our team's relentless drive, and Derek brings the leadership, scientific insight and passion for building mission-driven teams to help us reach new heights."
"Rezo's platform is uniquely positioned to address some of the biggest challenges in drug discovery. The strength of the board and leadership – and their commitment to pushing boundaries – was a huge factor in my decision to join the company," Derek said. "I look forward to working with the Rezo team and more deeply engaging with partners and investors who share in our mission to develop a differentiated product pipeline by modulating protein-protein interactions."
Comments powered by CComment